Table 2.
Palivizumab administration, (N = 304)
| n (%) | |
|---|---|
| Criteria for prophylactic administrationa | |
| Immunocompromised conditions | 167 (54.9) |
| a. Myelosuppressive chemotherapy | 68 (22.4) |
| b. Solid organ transplantation | 33 (10.9) |
| c. Hematopoietic stem cell allograft | 25 (8.2) |
| d. Immunosuppressive therapy | 21 (6.9) |
| e. Othersa | 17 (5.6) |
| On chronic peritoneal dialysis/hemodialysis | 16 (5.3) |
| Congenital nephrotic syndrome | 5 (1.6) |
| f. Primary immunodeficiency syndrome with abnormal T-cell function | 16 (5.3) |
| g. High-dose adrenocortical steroid therapy | 15 (4.9) |
| h. Autologous hematopoietic stem cell transplantation | 3 (1.0) |
| i. Bone marrow failure (e.g., aplastic anemia) | 3 (1.0) |
| j. Use of biologics | 2 (0.7) |
| k. Acquired T-cell dysfunction (e.g., AIDS) | 1 (0.3) |
| Down syndrome with no congenital heart disease | 138 (45.4) |
| 1. Marked megaloglossia/glossoptosis | 77 (25.3) |
| 2. Pulmonary hypertension | 29 (9.5) |
| 3. Airway obstruction due to respiratory tract malacia | 20 (6.6) |
| 4. Othersb | 12 (3.9) |
| 5. History of hospitalization due to viral infections/respiratory infections | 11 (3.6) |
| 6. Apnea | 4 (1.3) |
| 7. Pulmonary hypoplasia/dysplasia | 3 (1.0) |
| 8. Low lymphocyte or T-cell counts | 2 (0.7) |
| 9. Emphysematous lung | 1 (0.3) |
| Criteria for prophylactic administration (pooled)a | |
| Immunocompromised conditions | 167 (54.9) |
| Hematopoietic malignancy, solid tumor, bone marrow failure, hematopoietic stem cell transplantation and solid organ transplantationc | 126 (41.4) |
| Kidney disease, rheumatism/inflammatory disease and use of immunosuppressive drugd | 46 (15.1) |
| Congenital/acquired immunodeficiencye | 17 (5.6) |
| Down syndrome | 138 (45.4) |
| Status of final administration | |
| Completed | 260 (85.5) |
| Discontinueda | 44 (14.5) |
| Reason for discontinuation | |
| Failed to appear for a clinic visit/transferred to another hospital | 25 (8.2) |
| Others | 12 (3.9) |
| Adverse event | 7 (2.3) |
| Request of a family member | 1 (0.3) |
AIDS acquired immunodeficiency syndrome
aOne subject was counted more than once
bThe number of subjects with other findings only or unspecified findings was 13
cBased on criteria a, b, c, h, i for prophylactic administration [11]
dBased on criteria d, e, g, j for prophylactic administration [11]
eBased on criteria f and k for prophylactic administration [11]